ArticleCost effectiveness and resource allocation : C/E2026
External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo carry out external validation of the analysis of the budget impact of the drug fingolimod after its incorporation into the Brazilian Unified Health System, comparing the real parameters arising from its incorporation in the treatment of relapsing-remitting multiple sclerosis with the estimates presented in the incorporation report in 2017. This topic is highly pertinent and makes a valuable contribution to the sparse literature on real-world BIA validation, especially in low- and middle-income countries like Brazil, yielding crucial insights for enhancing health policy optimization.
methodsSurvey of the target population validated by demand measured through the dispensing of drugs, in the Brazilian Unified Health System of patients with multiple sclerosis; validation of the unit costs of drugs through purchases made by the Logistics Department of the Ministry of Health; determination of market share within the time horizon defined based on drugs purchases; estimation of direct administration costs; and monitoring of drugs to compare estimated values with the real value.
resultsDivergences were identified between real-life data collected in relation to the study's defined population and the market share of the drug fingolimod over the studied time horizon. There was a significant increase in the fingolimod market share, with the bigger market shares being in 2019 and 2020. The budget impact presented in the incorporation report was US$ 277,431,260.28, and the validated impact was US$ 194,955,442.76.
conclusionsThe validation process of the budget impact analysis of the incorporation of the drug fingolimod in 2017 resulted in savings of around US$ 82,4 million in relation to the value proposed for incorporation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.